凝血因子Ⅹa直接抑制剂的特异性逆转剂:andexanet alfa

A specific reversal agent for factor Ⅹa direct inhibitors: andexanet alfa

andexanet alfa是凝血因子Ⅹa直接抑制剂的特异性逆转剂,于2018年5月3日由美国食品和药物管理局批准上市,用于逆转利伐沙班、阿哌沙班的抗凝作用。andexanet alfa需弹丸式静脉注射,随后给予2 h持续静脉输注的给药方案,具有良好的安全性。

Andexanet alfa has been developed as reversal agent for factor Ⅹ a direct inhibitors, which has been approved to reverse anticoagulation of rivaroxaban and apixaban by the U.S. Food and Drug Administration on May 3, 2018. Andexanet alfa should be administered as an intravenous(IV) bolus, followed by continuous infusion for up to 2 hours, which has demonstrated a good safety.